Skip to main content
. 2019 Dec 6;11(12):1955. doi: 10.3390/cancers11121955

Table 2.

Treatment propositions for each case and patient.

Treatment 45 yo Patient
% (Nb)
75 yo Fit Patient
% (Nb; p *)
75 yo Unfit Patient
% (Nb; p **)
Case i (IIb)
Radiochemotherapy +/− surgery 59 (69) 64 (75; p = 0.33) 47 (55; p = 0.03)
Radiotherapy alone 2 (2) 2 (2; p = 1) 20 (23, p < 0.001)
Chemotherapy then radiochemotherapy 7 (8) 6 (7, p = 1) 4 (5, p = 0.57)
Chemotherapy then surgery 8 (9) 3 (4, p = 0.25) 3 (4, p = 0.25)
Surgery alone 5 (6) 3 (4; p = 0.75) 3 (4; p = 0.75)
Other 19 (23) 22 (25; p = 0.87) 22 (26; p = 0.75)
Case ii (IVa)
Radiochemotherapy +/− surgery 62 (72) 59 (69; p = 0.71) 35 (41; p < 0.001)
Radiotherapy alone 2 (2) 1 (1; p = 1) 20 (23; p < 0.001)
Chemotherapy then radiochemotherapy 17 (20) 15 (17; p = 0.72) 10 (12; p = 0.13)
Chemotherapy then surgery 3 (4) 1 (1; p = 0.37) 3 (3; p = 0.72)
Supportive care only 0 0 6 (7; p = 0.01)
Other 16 (17) 25 (27; p = 0.13) 26 (31; p = 0.03)
Case iii (IVb)
Chemotherapy doublet with platinum 60 (70) 55 (64; p = 0.51) 36 (42; p = 0.001)
Other chemotherapy +/− radiochemotherapy 12 (15) 15 (19; p = 0.58) 23 (26; p = 0.08)
Bevacizumab 42 (49) 33 (39; p = 0.22) 12 (15; p < 0.001)
Radiochemotherapy 10 (12) 10 (12; p = 1) 11 (13; p = 1)
Supportive care only 1 (1) 4 (5; p = 0.21) 15 (17; p < 0.001)
Other 16 (19) 15 (17; p = 0.86) 16 (19; p = 1)
Case iv (metastatic recurrence)
Chemotherapy 83 (97) 78 (91; p = 0.28) 54 (63; p < 0.001)
Bevacizumab 54 (63) 44 (52; p = 0.19) 18 (21; p < 0.001)
Chemotherapy if symptomatic 8 (9) 11 (13; p = 0.5) 18 (21; p = 0.001)
Supportive care only 0 2 (2; p = 0.5) 19 (22; p < 0.001)
Others 9 (11) 9 (11; p = 1) 9 (11; p = 1)

p < 0.05 are in bold. yo: year-old; * Comparison between 75 year-old fit patient and 45 year-old patient; ** Comparison between 75 year-old unfit patient and 45 year-old patient.